Infusion therapy for rheumatoid arthritis delivers powerful immune-targeting medications directly into your bloodstream through an IV line. These drugs, called biologics, work by blocking specific parts of the immune system that drive joint inflammation and damage. They’re typically reserved for people whose RA hasn’t responded well to first-line treatments like methotrexate, and across studies, roughly 53% of patients on biologics achieve remission, with that number climbing to 67% after 6 to 12 months of follow-up.
How Infusion Biologics Target RA
Rheumatoid arthritis is driven by an immune system that mistakenly attacks the lining of your joints. Infusion biologics work by intercepting specific immune signals responsible for that attack. Different drugs target different parts of the process, and your rheumatologist will choose one based on your disease activity and treatment history.
The largest category blocks a protein called TNF-alpha, which acts as a master switch for inflammation. TNF-alpha activates white blood cells, triggers other inflammatory signals, and even stimulates the cells that break down bone. Infliximab is the most commonly infused TNF blocker. By neutralizing TNF-alpha before it can bind to its receptors, these drugs quiet the inflammatory cascade at its source.
Other infused biologics take different approaches. Rituximab depletes a specific type of immune cell (B cells) that contributes to joint inflammation. Abatacept blocks the activation signal that T cells need to mount an immune attack. Tocilizumab targets a different inflammatory protein called IL-6, which plays a central role in RA-related swelling, pain, and fatigue. Each of these drugs reaches immune targets that oral medications can’t effectively address, which is why they can work when earlier treatments have failed.
What Happens During an Infusion
You’ll receive infusions at a clinic, hospital outpatient center, or specialized infusion suite. A nurse places an IV line, typically in your arm, and the medication drips into your bloodstream over a set period. Session length varies significantly by drug. Rituximab infusions, for example, run four to five hours the first time and around three hours for later sessions, though some centers now use a 90-minute accelerated protocol. Other biologics like abatacept tend to be shorter, often around 30 minutes once you’re past the initial doses.
Before the infusion starts, you’ll likely receive pre-medications to reduce the chance of a reaction. These commonly include acetaminophen and an antihistamine. Since sessions can last several hours, it helps to bring something to pass the time: a book, headphones, your phone. Eating beforehand is generally a good idea, though check with the facility about bringing snacks. A sweater or blanket is worth packing too, since infusion rooms tend to run cool.
Infusion Schedules and Frequency
The dosing schedule depends on which biologic you’re receiving. Most infusion drugs start with a loading phase, where you get doses more frequently to build up therapeutic levels, followed by a maintenance phase with longer intervals. Infliximab, for instance, is given at weeks 0, 2, and 6, then every 8 weeks afterward. Rituximab follows a different pattern: two infusions spaced two weeks apart, with repeat courses typically every 6 months depending on how your disease responds. Abatacept is given monthly after an initial loading period.
Your rheumatologist may adjust the timing based on how well the drug controls your symptoms. Some people need more frequent dosing, while others maintain remission on extended intervals.
Side Effects and Infusion Reactions
The most immediate concern is an infusion reaction, which can include flushing, itching, headache, nausea, or changes in blood pressure during or shortly after the session. In one study of rituximab in RA patients, about 23% of patients experienced at least one infusion reaction, though most were mild. These reactions occurred in roughly 8% of total infusions administered. Pre-medications help reduce this risk, and nurses monitor your vital signs throughout the process.
The more significant long-term risk is infection. Because these drugs suppress parts of the immune system, your body becomes less effective at fighting off bacteria and viruses. Infection rates in RA patients on rituximab have been measured at around 13%. Before starting infusion therapy, your doctor will screen you for latent infections like tuberculosis and hepatitis B, since these drugs can reactivate dormant infections. You’ll also want to stay current on vaccinations, ideally before beginning treatment.
IV Infusions vs. Self-Injected Biologics
Several biologics now come in both IV and subcutaneous (self-injected) forms. When the same drug is available both ways, efficacy and safety are generally comparable. The real difference comes down to lifestyle and preference.
In studies of RA patients, about two-thirds preferred subcutaneous injections over IV infusions. The main reasons were convenience, the ability to treat at home, less time commitment, and greater independence. The one-third who preferred IV infusions cited the comfort of having a healthcare professional present, feeling safer in a clinical setting, and the less frequent dosing schedule that IV routes often allow.
Some biologics are only available as infusions. Rituximab, for example, is given intravenously, and its dosing schedule (two infusions every six months) means fewer total treatment days per year compared to weekly or biweekly self-injections of other drugs. Your rheumatologist will factor in disease severity, insurance coverage, and your personal preferences when recommending a route.
Cost and Insurance Coverage
Infusion biologics are expensive, and navigating coverage can be one of the more frustrating parts of treatment. Nearly all Medicare Part D plans (97%) require prior authorization before approving a biologic, and most place these drugs in specialty tiers with percentage-based coinsurance rather than flat copays. The average coinsurance rate runs about 30% of the drug’s cost, translating to mean out-of-pocket expenses of roughly $830 to $860 per month before reaching catastrophic coverage thresholds.
Many insurers also require “step therapy,” meaning you must try and fail less expensive medications (usually methotrexate) before they’ll approve a biologic. Most drug manufacturers offer patient assistance programs or copay cards that can significantly reduce your share of the cost. Your infusion center’s financial counselor or your rheumatologist’s office can help you navigate these options.
One additional cost consideration: because IV infusions are administered in a clinical setting, they’re often billed under medical benefits (like Medicare Part B) rather than pharmacy benefits. This can sometimes work in your favor, depending on your plan’s structure, since medical benefit copays may be lower than specialty pharmacy coinsurance.